ELCC 2016: Phase 2 trial of BI 1482694 (HM61713), third-generation TKI, in T790M-positive NSCLC

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses a phase 2 trial of the efficacy and safety of BI 1482694 (HM61713), a third-generation epidermal growth factor receptor (EGFR) mutant-specific tyrosine kinase inhibitor (TKI), for the treatment of patients with T790M-positive non-small cell lung cancer (NSCLC).